Trial Profile

A phase2 trial of durvalmab in stage 3 chemoradiotherapy ineligible NSCLC patients following radiation therapy alone

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 01 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use
Acronyms SPIRAL-RT

Most Recent Events

22 Oct 2023 Results assessing efficacy and safety of durvalumab after radiation monotherapy for NSCLC patients who are ineligible for chemoradiotherapy published in the European Journal of Cancer
30 Jun 2022 Status changed from active, no longer recruiting to completed.
16 Jun 2021 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com